Enhanced Recovery Stem-Cell Transplantation: Multidisciplinary Efforts to Improve Outcomes in Older Adults Undergoing Hematopoietic Stem-Cell Transplant. Issue 3 (10th March 2023)
- Record Type:
- Journal Article
- Title:
- Enhanced Recovery Stem-Cell Transplantation: Multidisciplinary Efforts to Improve Outcomes in Older Adults Undergoing Hematopoietic Stem-Cell Transplant. Issue 3 (10th March 2023)
- Main Title:
- Enhanced Recovery Stem-Cell Transplantation: Multidisciplinary Efforts to Improve Outcomes in Older Adults Undergoing Hematopoietic Stem-Cell Transplant
- Authors:
- Ngo-Huang, An
Ombres, Rachel
Saliba, Rima M.
Szewczyk, Nicholas
Adekoya, LaToya
Soones, Tacara N.
Ferguson, Jill
Fontillas, Rhodora C.
Gulbis, Alison M.
Hosing, Chitra
Kebriaei, Partow
Lindsay, Richard
Marin, David C.
Mehta, Rohtesh S.
Alousi, Amin M.
Srour, Samer
Oran, Betul
Olson, Amanda L.
Qazilbash, Muzaffar H.
Rivera, Zandra
Champlin, Richard E.
Shpall, Elizabeth J.
Popat, Uday R. - Abstract:
- Abstract : PURPOSE: Older adults have unique risk factors for poor outcomes after hematopoietic stem-cell transplant (HSCT). We sought to determine the impact of our multidisciplinary supportive care program, Enhanced Recovery after stem-cell transplant (ER-SCT), on survival outcomes in patients age 65 years and older who underwent HSCT. PATIENTS AND METHODS: In this retrospective study, clinicodemographic data, nonrelapse mortality (NRM), overall survival (OS), and relapse were compared between 64 patients age 65 years and older who underwent allogeneic stem-cell transplant during ER-SCT program's first year, October 2017 through September 2018, and 140 historical controls age 65 years and older who underwent allogeneic HSCT, January 2015 through September 2017. RESULTS: In the ER-SCT cohort, 41% (26 of 64) of patients were women, and the median (range) age was 68 (65-74) years; in the control cohort, 38% (53 of 140) of patients were women, and the median (range) age was 67 (65-79) years. Hematopoietic cell transplant comorbidity index and donor type/cell source were similar between cohorts. The ER-SCT cohort had a lower 1-year NRM rate (13% v 26%, P = .03) and higher 1-year OS rate (74% v 53%, P = .007). Relapse rate did not differ significantly between cohorts. In multivariate analyses, ER-SCT was associated with improved 1-year NRM (hazard ratio, 0.4; 95% CI, 0.2 to 0.9; P = .02) and improved 1-year OS (hazard ratio, 0.5; 95% CI, 0.3 to 0.9; P = .03). CONCLUSION: AAbstract : PURPOSE: Older adults have unique risk factors for poor outcomes after hematopoietic stem-cell transplant (HSCT). We sought to determine the impact of our multidisciplinary supportive care program, Enhanced Recovery after stem-cell transplant (ER-SCT), on survival outcomes in patients age 65 years and older who underwent HSCT. PATIENTS AND METHODS: In this retrospective study, clinicodemographic data, nonrelapse mortality (NRM), overall survival (OS), and relapse were compared between 64 patients age 65 years and older who underwent allogeneic stem-cell transplant during ER-SCT program's first year, October 2017 through September 2018, and 140 historical controls age 65 years and older who underwent allogeneic HSCT, January 2015 through September 2017. RESULTS: In the ER-SCT cohort, 41% (26 of 64) of patients were women, and the median (range) age was 68 (65-74) years; in the control cohort, 38% (53 of 140) of patients were women, and the median (range) age was 67 (65-79) years. Hematopoietic cell transplant comorbidity index and donor type/cell source were similar between cohorts. The ER-SCT cohort had a lower 1-year NRM rate (13% v 26%, P = .03) and higher 1-year OS rate (74% v 53%, P = .007). Relapse rate did not differ significantly between cohorts. In multivariate analyses, ER-SCT was associated with improved 1-year NRM (hazard ratio, 0.4; 95% CI, 0.2 to 0.9; P = .02) and improved 1-year OS (hazard ratio, 0.5; 95% CI, 0.3 to 0.9; P = .03). CONCLUSION: A multidisciplinary supportive care program may improve NRM and OS in older patients undergoing allogeneic HSCT. Randomized studies are warranted to confirm this benefit and explore which program components most contribute to the improved outcomes. … (more)
- Is Part Of:
- JCO oncology practice. Volume 19:Issue 3(2023)
- Journal:
- JCO oncology practice
- Issue:
- Volume 19:Issue 3(2023)
- Issue Display:
- Volume 19, Issue 3 (2023)
- Year:
- 2023
- Volume:
- 19
- Issue:
- 3
- Issue Sort Value:
- 2023-0019-0003-0000
- Page Start:
- e417
- Page End:
- e427
- Publication Date:
- 2023-03-10
- Subjects:
- Oncology -- Periodicals
Medical Oncology
Neoplasms
Oncology
Periodicals
616.994 - Journal URLs:
- https://ascopubs.org/journal/jop ↗
http://journals.lww.com/pages/default.aspx ↗ - DOI:
- 10.1200/OP.22.00520 ↗
- Languages:
- English
- ISSNs:
- 2688-1527
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 26785.xml